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Kaposi’s Sarcoma-Associated Herpesvirus Glycoproteins B and K8.1
Regulate Virion Egress and Synthesis of Vascular Endothelial
Growth Factor and Viral Interleukin-6 in BCBL-1 Cells䌤
R. Subramanian,1 I. Sehgal,2 O. D’Auvergne,3 and K. G. Kousoulas1*
Division of Biotechnology and Molecular Medicine and Department of Pathobiological Sciences1 and Department of Comparative
Biomedical Sciences,2 School of Veterinary Medicine, Louisiana State University, Baton Rouge, Louisiana, and Department of
Biological Sciences, Southern University & A&M College, Baton Rouge, Louisiana3

Kaposi’s sarcoma-associated herpesvirus (KSHV) viral glycoproteins play important roles in the infectious life
cycle and have been implicated in KSHV-associated endothelial cell transformation, angiogenesis, and KS-induced
malignancies. KSHV-associated primary effusion lymphomas (PELs) secrete high levels of vascular endothelial
growth factor (VEGF) and viral interleukin-6 (vIL-6) in vitro and VEGF, vIL-6, and basic-fibroblast growth factor
(b-FGF) in mouse xenografts. KSHV-encoded glycoproteins B (gB) and K8.1 stimulate VEGF secretion, most likely
mediated by direct or indirect binding to cell surface receptors, including the gB-specific ␣V␤3 and ␣3␤1 integrins.
In this study, the short interfering RNA (siRNA)-mediated inhibition of either gB or K8.1 transcription by anti-gB
or -K8.1 siRNAs caused a substantial reduction in virion egress and a decrease in both vIL-6 and VEGF production.
Similarly, the treatment of BCBL-1 cells with anti-gB or anti-K8.1 antibodies caused a substantial reduction in
vIL-6 and VEGF production. Codon-optimized versions of either wild-type gB, mutant gB having the RGD amino
acid motif changed to RAA, or K8.1 efficiently rescued virion egress and VEGF and vIL-6 production. These results
suggest that the binding of gB via its RGD motif to integrin receptors was not responsible for the observed
gB-associated regulation of VEGF and vIL-6 transcription. Conditioned medium collected from BCBL-1 cells
transfected with anti-gB and anti-K8.1 siRNAs or treated with anti-gB and anti-K8.1 antibodies exhibited a
significantly reduced ability to induce the formation of the capillary network of endothelial cells compared to the
ability of medium from mock-infected BCBl-1 cells. Furthermore, medium obtained from BCBL-1 cells expressing
smaller amounts of gB and K8.1 produced a substantial reduction in endothelial cell migration in a vertical
migration assay compared to that of control medium containing wild-type levels of gB and K8.1. These results
suggest a functional linkage between gB/K8.1 synthesis and VEGF/vIL-6 transcriptional regulation via paracrine
and/or autocrine signaling pathways.
virus glycoproteins. It is an essential virion component for members of the alpha- and betaherpesvirus subfamilies and functions
in virion attachment and virus entry into susceptible cells (10, 14,
41). KSHV virions incorporate gB in the viral envelope, which is
important for attachment to cell surfaces and entry via an RGDdependent binding to integrins. Initially, the ␣3␤1 integrin was
implicated (3), but more recently, it was shown that ␣V␤3 is the
integrin involved in gB RGD-mediated virus entry (19). KSHV
gB is a type 1 membrane glycoprotein 845 amino acids (aa) in
length (7, 44, 46). It contains a predicted signal sequence of 23 aa,
an extracellular domain containing multiple glycosylation sites
and multiple hydrophobic regions, of which the carboxyl-most
terminal region serves to anchor gB in membranes (7, 44–46). gB
has been shown to be involved in the egress of herpesviruses,
including pseudorabies virus (PRV; alphaherpesvirus) and Epstein-Barr virus (gamma-1-herpesvirus) (9, 25, 28, 40, 41). KSHV
gB also was shown to be essential for virion egress in 293 cells
(27). Recently, we demonstrated that KSHV gB is important for
virion egress in BCBL-1 cells, while the carboxyl terminus of gB
is not (33). In contrast to these examples, herpes simplex virus
type 1 (HSV-1) gB is not required for virion egress (11).
Glycoprotein K8.1A has 228 amino acids (aa) and contains
a signal sequence, a transmembrane domain, and four N-glycosylation sites. A smaller glycoprotein, K8.1B, is formed by
the differential splicing of the K8.1 transcript, resulting in a

Kaposi’s sarcoma-associated herpesvirus (KSHV), also referred to as human herpesvirus 8 (HHV-8), is a member of the
gamma-2-herpesvirus family (genus Rhadinovirus) (36, 51).
KSHV is etiologically associated with Kaposi’s sarcoma, primary effusion or body cavity-based lymphoma, and multicentric Castleman’s disease (4, 18, 54). Typically, all herpesviruses
initiate infection by the binding of several viral glycoproteins
embedded within the viral envelope to specific receptors on
cell surfaces. Viral glycoproteins also mediate the fusion of the
viral envelope with either cellular or endosomal membranes
and function in the final stages of virion morphogenesis and
egress (23, 34, 50).
KSHV codes for a number of glycoproteins, some of which
have significant homology to glycoproteins of other herpesviruses.
These include glycoproteins gB (ORF8) (38), gH (ORF22), gM
(ORF39), gL (ORF47) (36, 51), and gN (ORF53) (12, 26, 51).
KSHV also encodes additional glycoproteins that do not have
homologs in other herpesviruses, including gpK8.1A, gpK8.1B,
K1, K14, and K15, which are expressed during lytic replication
(51). Glycoprotein B (gB) is one of the most conserved herpes* Corresponding author. Mailing address: Department of Pathobiological Sciences, School of Veterinary Medicine, Louisiana State University, Baton Rouge, LA. Phone: (225) 578-9682. Fax: (225) 578-9701.
E-mail: vtgusk@lsu.edu.
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TABLE 1. Primers used in this study
Name of primer

Oligonucleotide sequencea

Expected DNA
fragment size (bp)

gBUNI (gB universal; forward)
gBUNI (gB universal; reverse)
GAPDH (forward)
GAPDH (reverse)
ORF59 (forward)
ORF59 (reverse)
ORF59 (probe)
K8.1A FP1
K8.1A RP1
K8.1A FP2
K8.1A RP2
K8.1A FP3
K8.1A RP3
gBr-F
gBr-R
K8.1 (forward)
K8.1 (reverse)
vIL6 (forward)
vIL6 (reverse)
Hu VEGF (forward)
Hu VEGF (reverse)

TCCAGACTACCCACGAGGAC
GTCAGGTTAATCGCGGACAT
GATTCCACCCATGGCAAATT
AAGATGGTGATGGGATTTCCATT
TCAGCTTCAGGAATACGTCCG
GGCTATGCCAGCGTCGAGTA
FAM-CGCGTGAGCTATTCGGTGCGAATA-TAMRA
AACTGCAGCTACGAGAACATGACGGCCCTAGAGGCCGTGCTC
GCCGCTCTCGTCGATGGCGTCCTCTCCAGACCCAGAGGCAGAC
ATGAGTTTCTAGAATGAGTTCCACACAGATTCGC
CATGTTCTCGTAGCTGCAGTTCATCCTGCCTAGCCAGTCCT
AGGACGCCATCGACGAGAGCGGCTCGGGGGAGGAAGAGCGTCC
ATAGTTGGATCCGTGTTACTCTATGTAGGGTTT
CTCACAGCAGGGCTGCCACCTTCCAGA
TCTGGAAGGTGGCAGCCCTGCTGTGAG
TTATCAGGACTGGCTAGGCAG
AGGCTGATATTAAGGCATCG
TTGTGGTCTCTCTTGCTGGT
TGAAGCCTCCCTAATAGACC
TGGACATCTTCCAGGAGTACCCTGA
ACAAATGCTTTCTCCGCTCTGAGCAA

240

183
137
370

260
460
350

FAM, 6-carboxyfluorescein; TAMRA, carboxytetramethylrhodamine. Italicized nucleotides represent the RAA mutated amino acid sequence.

glycoprotein of 167 aa having three N-glycosylation sites. However, K8.1A is found predominantly in infected cells and within
virion envelopes (12, 67, 68). K8.1A binds to heparin sulfate
moieties on cell surfaces, facilitating virion binding to cells
(62). Soluble versions of K8.1A were shown to activate the
gamma/beta interferon (IFN-␣/␤) signaling pathway, inducing
an antiviral state (43).
The KSHV-induced upregulation of different angiogenic
factors is thought to be involved in KS development and progression. Specifically, a number of recent studies have shown
that the KSHV infection of endothelial cells induces angiogenesis and invasive phenotypes by inducing angiogenic and inflammatory cytokines, such as Ang-2, MMP1, MMP9, and IL-6
(47, 48, 64, 65). A number of KSHV-encoded proteins, including K1, vGPCR, and vIL-6, have been reported to induce the
major angiogenic factor VEGF-A, suggesting its involvement
in KSHV pathogenesis (5, 8, 56, 63). Soluble versions of viral
glycoprotein K8.1A alone or gB and K8.1A added together to
cultured human microvascular endothelial cells (HMVEC-d) upregulated VEGF-A synthesis. However, treatment with soluble
gB alone did not induce significant levels of VEGF-A. These
results suggested that the binding of KSHV via K8.1 and gB on
cell surfaces is sufficient to induce signal transduction pathways
that lead to the upregulation of VEGF-A synthesis (55).
Previous experiments from our laboratory have indicated
that glycoprotein K8.1A was dispensable for viral infectivity in
293T cells. This conclusion was based on the generation of a
KSHV mutant virus that carried a deletion of the K8.1 gene
constructed on the KSHV genome cloned into a bacterial
artificial chromosome (bac) (30). In this study, we show that
the inhibition of K8.1 synthesis in BCBL-1 cells by anti-K8.1
short interfering RNAs (siRNAs) inhibited virion egress in a
manner similar to that produced by the inhibition of gB synthesis (57). Importantly, we show for the first time that the
inhibition of either gB or K8.1 synthesis in BCBL-1 cells causes

significant inhibition of both VEGF and vIL-6 production. The
fact that the treatment of BCBL-1 cells with anti-gB and antiK8.1 antibodies causes a similar inhibition of VEGF and vIL-6
production suggests that gB and K8.1 function via paracrine/
autocrine signaling pathways to regulate VEGF and vIL-6 production.
MATERIALS AND METHODS
Cell lines and media. BCBL-1 cells harboring rKSHV.152 (61) and expressing
green fluorescent protein (a gift from Jeff Vieira, University of Washington)
were cultured in RPMI 1640 (Hyclone) medium with 10% heat-inactivated fetal
bovine serum (FBS) (Hyclone) and 2 mM L-glutamine, 1% penicillin-streptomycin (pen/strep) (Gibco), and 250 mg of G418/ml (Gibco). 293T cells (ATCC)
were maintained in Dulbecco’s modified Eagle’s medium (DMEM) with 10%
FBS and 1% pen/strep. The KSHV lytic cycle was induced in BCBL-1 cells by the
addition of 25 ng/ml of 12-O-tetradecanoylphorbol-13-acetate (TPA; Sigma, St.
Louis, MO) for 12 to 48 h. Human umbilical vein endothelial cells (HUVECs)
were purchased from Lonza Biotech and maintained per the supplier’s instructions.
Antibodies. Rabbit polyclonal antibodies generated in our laboratory against
KSHV gB peptides were used to detect gB protein in Western blot analysis (7).
Mouse monoclonal antibodies against Hu-VEGF (ABCAM) or Hu-GAPDH
(R&D systems), and rabbit antibody against K8.1 (Santa Cruz Biotechnology,
Inc.) or gB (produced in this laboratory), were used to detect the respective
proteins from conditioned medium or from cell lysates.
Vector construction. The short hairpin RNAs (shRNAs) against gB (57) and
K8.1A were cloned in p3xFLAG vector. The two K8.1 shRNA oligonucleotides
(si-5 and si-10) were designed with flanking restriction sites HindIII and NotI for
si-5 (top strand, AGCTTCTGTTCCTACGAGAATATGTTCAAGAGACATA
TTCTCGTAGGAACAGTTGC; bottom strand, GGCCGCAACTGTTCCTAC
GAGAATATGTCTCTTGAACATATTCTCGTAGGAACAGA) and XbaI
and BamHI for si-10 (top strand, CTAGAGATGCAATAGATGAATCGGTT
CAAGAGACCGATTCATCTATTGCATCTTG; bottom strand, GATCCAAG
ATGCAATAGATGAATCGGTCTCTTGAACCGATTCATCTATTGCATCT).
The short hairpin oligonucleotides were cloned in p3xFLAG vector as described
earlier (57). BAC 36 carrying the KSHV genome was used to amplify the
wild-type K8.1A gene using the primers K8.1-FP1 and K8.1-RP3. The sitedirected mutagenesis of the wild-type K8.1A gene at the siRNA target regions of
si-5 (bp 163 to 183) and si-10 (bp 299 to 319) was carried out using the six primers
of K8.1 FP1-RP3 described in Table 1. The codon-altered K8.1 was cloned in
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p3xFlag vector either individually or in combination with si-5 or si-10. In the case
of glycoprotein B, site-directed mutagenesis at the RGD motif (amino acids 27
to 29) of codon-optimized glycoprotein B (ps18⫹gBco) (57) was carried out
using the gBr-F and gBr-R primers (Table 1) to generate pgBR.
Transient transfection of BCBL-1 cells. The transient transfection of
BCBL-1 cells was carried out in six-well plates using the Superfect (Qiagen)
transfection agent according to the manufacturer’s instructions and as described previously (57).
Reverse transcription-PCR (RT-PCR). The lytic replication of KSHV was
induced by resuspending transiently transfected BCBL-1 cells in serum-containing RPMI 1640 medium supplemented with 25 ng/ml TPA 24 h posttransfection.
Cells were transfected with plasmids expressing either a nonspecific siRNA, an
siRNA against K8.1, an siRNA against gB, siRNAs against both gB and K8.1, or
medium without additives. The cells were pelleted at 1,500 rpm for 10 min.
Harvested cells were resuspended in 500 l of ice-cold PBS and split into two
parts for RNA extraction (200 l) and Western blot analysis (300 l). Total RNA
was extracted using the Nucleospin RNA II kit from Clontech Laboratories by
following the manufacturer’s instructions. First-strand cDNA was prepared using
the high-capacity reverse transcription kit from Applied Biosystems by following
the manufacturer’s instructions. Equal quantities of first-strand cDNA were used
for PCR using the universal gB primers, primers for K8.1, VEGF, IL-6, IL-6R,
and the primers for glyceraldehyde phosphate dehydrogenase (GAPDH) (Table
1). The PCR products were resolved by electrophoresis on a 1% agarose gel,
quantified by densitometry, and normalized to levels of GAPDH. GAPDH levels
remained relatively constant in all experiments.
Western blot analysis. Total soluble protein was extracted and quantified from
transiently transfected 293 and BCBL-1 cells as described earlier (57). Mouse
monoclonal antibodies against Hu-VEGF (ABCAM), IL-6 (R&D systems), and
Hu-GAPDH were used as primary antibodies. Horseradish peroxidase (HRP)tagged anti-rabbit/anti-mouse antibodies were used as secondary antibodies.
Immobilon (Millipore) Western blotting detection reagent was used for the
chemiluminescent detection of proteins.
Microtubule formation to study angiogenesis. The microtubule formation
assay was adopted from previously published work (31). Specifically, transiently
transfected BCBL-1 cells were resuspended in RPMI 1640 medium containing 25
ng/ml TPA 24 h posttransfection. For the antibody treatment experiments, anti-gB
or anti-K8.1 antibodies were added to the medium during the TPA treatment
cycle at a concentration of 1 g/ml. After a 24-h induction with TPA, this
medium was removed and replaced with fresh RPMI medium without serum for
an additional 24 h.
HUVECs (5 ⫻ 104/well) were seeded in an eight-well chamber slide pretreated
with 0.1% glycerin. Total protein in the conditioned medium from BCBL-1 cells
was quantified using a bicinchoninic protein assay kit (Pierce Inc.), and equal
amounts of protein from each sample were layered over the HUVECs. The
volume was made up with serum-free HUVEC medium. After 48 h, the cells
were fixed in ice-cold methanol for 20 min and stained with hemolysin and eosin
to visualize microtubule formation representing in vitro angiogenesis. The microtubules were visualized and imaged under 2.5⫻ magnification, and five random viewing fields from each sample were counted. Angiogenesis was quantified
by counting the number of branch points and the total number of branches per
point, with the product indicating the degree of angiogenesis. The scoring of
angiogenesis was performed in a double-blinded fashion, having two independent observers score each treatment.
Migration assay for endothelial cells (Boyden chamber assay). A vertical
migration assay described previously (32) was adopted to determine the potential
of medium conditioned by BCBL1 cells (c.m.) to serve as a chemoattractant for
HUVECs. Specifically, BCBL-1 cell supernatants were collected in the same way
as that described for the microtubule formation assay. For this assay, 30,000
HUVEC cells (purchased from Lonza Group) were suspended in 200 l of a 1:5
(vol/vol) mixture of HUVEC growth medium. Opti-MEM (Invitrogen Corporation) was applied to the upper chamber of a transwell insert (8.0-m pore size;
catalog no. 353097; BD Falcon). The bottom chamber was filled with 600 l of
BCBL1 c.m. standardized to uniformly contain 1.4 mg/ml total protein. In addition, a positive chemoattractant control consisting of VEGF (10.0 ng/ml; Biosource Invitrogen) in RPMI 1640 medium was included. HUVEC migration was
allowed to proceed for 6 h at 37°C, after which inserts were removed and cells
remaining on the upper surface of the membrane were swabbed away with a
cotton applicator. Cells that migrated to the insert’s bottom surface were
stained with hematoxylin and eosin and counted. Results are expressed as
cells per 400⫻ objective field. Five regions from each of three inserts per
condition were averaged.
TaqMan real-time PCR analysis. Real-time PCR was carried on viral DNA
from cell pellets and supernatants of BCBL-1 cells as mentioned above. The
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FIG. 1. Schematic diagram of plasmid vectors used in transfection
experiments. (A) p3xFLAG vector carrying anti-K8.1 siRNAs siK5 and
siK10 (ps5/s10). The siK5- and siK10-encoding gene cassettes also
were cloned individually at the restriction sites indicated to generate
vectors ps5 and ps10 (not shown). (B) The nucleotide sequence of K8.1
was altered at the target region of siK5 (166 bp) and siK10 (299 bp)
and cloned downstream of siK5 to generate the vector ps5/K8.1co. The
codon-altered K8.1 and siK5 gene cassettes are separated by a 52-bp
encephalomyocarditis virus internal ribosome entry site (ECMV
IRES). (C) The ps18/gbco plasmid vector coexpressing anti-gB siRNA
si18 and codon-optimized gB was used to generate the plasmid vector
ps18/gBR, which carries the RGD-RAA mutation from amino acids 27
to 29 instead of the gB wild-type gene.

primers and probe (6-carboxytetramethylrhodamine [TAMRA]) for the realtime PCR were designed to detect ORF 59 (Table 1). Supernatants were collected 48 h postinduction, and 200 l was used for the extraction of viral DNA.
The supernatants were treated with turbo DNase I (Ambion) for 2 h at 37°C.
Viral DNA was extracted using the DNeasy blood and tissue kit (Qiagen) per the
manufacturer’s instructions. Equal volumes of viral DNA were used for TaqMan
PCR analysis. KSHV BAC 36 DNA was used to generate the standard curve.

RESULTS
The effect of glycoproteins gB and K8.1 synthesis on virion
egress from BCBL-1 cells. Previous work in this laboratory has
shown that gB synthesis can be inhibited effectively by anti-gB
siRNAs. Furthermore, gB synthesis can be restored upon the
transient expression of codon-optimized gB genes containing
analogous gene sequences not recognized by the anti-gB
siRNAs (57). In this study, different plasmid vectors were utilized to regulate gB and K8.1 synthesis (Fig. 1). Plasmid ps18/
gBco expressing the si18 anti-gB siRNA and a codon-optimized version of gB has been described previously (57). Sitedirected mutagenesis was utilized to construct the plasmid
vector ps18/gBR expressing a gBco gene specifying RGD-toRAA amino acid changes. Similar plasmid vectors were constructed to express the anti-K8.1 siRNAs siK5 (ps5) and siK10
(ps10), either separately or together (ps5/s10). One more plasmid (ps5/K8.1co) was constructed to express the K8.1 codonmodified sequence (K8.1co) together with the siK5 siRNA.
The transfection of BCBL-1 cells with plasmid ps5 reduced
K8.1 mRNA levels by approximately 50%, as evidenced by the
reduction in the K8.1-specific RT-PCR product. Transfection
with plasmid ps5/K8.1co produced mRNA levels similar to
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FIG. 2. Effect of inhibition of K8.1 and/or gB synthesis on virion egress. (A) BCBL-1 cells were transfected with plasmid vectors expressing
nonspecific siRNA, ps5, or ps5/K8.1co (expressing a codon-altered K8.1 gene and siK5). Cell pellets were collected 16 h postinduction, and total
RNA was extracted. First-strand cDNAs were produced and amplified by PCR using oligonucleotide primers described in Table 1, and the
resultant 350-bp DNA fragment was quantified by densitometry and normalized to GAPDH. (B) BCBL-1 cells were transfected with plasmid
vectors expressing nonspecific siRNA, ps5/s10, ps18⫹ps22, ps5/s10 ⫹ ps18⫹ps22, or ps5/K8.1co (expressing a codon-altered K8.1 gene and siK5).
Cells were induced (⫹) or not induced (⫺) with TPA 24 h posttransfection, supernatants were collected 48 h postinduction, and viral DNA was
extracted and quantified via PCR. (C) Experiments were performed as described for panel B to investigate whether altering the gB RGD to RAA
had any effect on virion egress. BCBL-1 cells were transfected with plasmid vectors expressing nonspecific siRNA, ps18, ps18/gBco, and ps18/gBR
and were assayed for viral DNA as described for panel B. All experiments were conducted in triplicate, and error bars represent standard errors
of the means (SEM). (D) Quantitative PCR analysis results of intracellular and extracellular viral DNA. Quantitative PCR was performed using
oligonucleotide primers specific for KSHV ORF59 as described previously (57) (also see Materials and Methods).
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FIG. 3. Effect of K8.1 and/or gB inhibition on VEGF production. (A) BCBL-1 cells were transfected with plasmid vectors expressing
nonspecific siRNA, ps5 (K8.1 target), or ps5/K8.1co. Cells were induced with TPA (⫹) or left uninduced ([) starting at 24 h posttransfection. Cell
pellets were collected 16 h postinduction, and total RNA was extracted. First-strand cDNAs were produced and amplified by PCR using primers
described in Table 1, and the resultant 250-bp DNA fragments were quantified by densitometry and normalized to GAPDH. (B) Experiments
similar to those described for panel A using plasmid vectors expressing nonspecific siRNA, ps18, ps18⫹gBco, and ps18⫹gBR. (C) Experiments
similar to those described for panels A and B with plasmid vectors expressing nonspecific siRNA, ps5/s10, ps18⫹ps22, and ps5/s10 ⫹ ps18-22. Cells
were induced with TPA (⫹) 24 h posttransfection or left uninduced (⫺), supernatants were collected 48 h postinduction, and the total amount of
protein was determined. Equal amounts of protein from the supernatants were loaded on SDS-PAGE gels. Experiments were conducted in
triplicate, and error bars represent SEM. The bar graphs represent the densitometric analysis results obtained using the Image J software.
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those observed in BCBL-1 cells transfected with a plasmid
encoding a nonspecific siRNA or TPA-induced, but not transfected, BCBL-1 cells (Fig. 2A). Previously, we demonstrated
that the inhibition of gB synthesis caused the inhibition of
virion egress from BCBL-1 cells (57). Similar experiments were
performed to investigate the potential role of K8.1 in virion
egress. The transfection of BCBL-1 cells with a plasmid expressing both anti-K8.1 siRNAs (ps5/s10) resulted in a substantial reduction of virion egress comparable to that produced
by transfection with the anti-gB siRNAs. The simultaneous
transfection of both anti-gB (ps18⫹ps22) and anti-K8.1 (ps5/
s10) plasmid vectors also produced similar levels of egress
inhibition. The transfection of BCBL-1 cells with plasmid vector ps5/K8.1co expressing the codon-altered K8.1 and the siK5
siRNA efficiently rescued virion egress (Fig. 2B). To further
assure that siRNA expression did not affect viral replication,
the total amount of viral DNA within BCBL-1 cells was determined and compared to the amount of viral DNA found within
virion particles from their respective supernatants. The total
viral DNA within BCBL-1 cells remained relatively constant
irrespective of the treatment with the various plasmids expressing siRNAs and the codon-optimized gB or K8.1 (Fig. 2D).
The gB RGD amino acid motif does not function in virion
egress. The amino terminus of gB contains an RGD amino
acid motif, which is important for binding to its cognate receptors ␣V␤3 and/or ␣3␤1 on KSHV-susceptible cells (2, 19). This
gB binding induces integrin-dependent signaling pathways that
regulate a number of important cellular and viral processes
(60). To investigate whether the gB RGD motif was important
in virion egress from BCBL-1 cells, BCBL-1 cells were transfected with plasmid ps18/gBco or ps18/gBR, both of which
inhibit the endogenous wild-type gB synthesis through the action of the s18 siRNA while simultaneously encoding either the
codon-optimized gB or codon-optimized gB carrying the
RGD-to-RAA mutations. gBR rescued virion egress as efficiently as the gBco-expressing plasmid (Fig. 2C).
Inhibition of gB and K8.1 synthesis causes inhibition of
VEGF mRNA levels. Previous studies have shown that soluble
versions of either gB or K8.1 enhanced the production of
VEGF (55). To investigate the potential effects of gB and K8.1
inhibition on VEGF and vIL-6 production, the relative levels
of VEGF and vIL-6 mRNAs were assessed by RT-PCR (see
Materials and Methods) (Fig. 3). The transfection of BCBL-1
cells with the anti-K8.1 siRNAs (ps5) caused an approximately
35% inhibition of VEGF mRNA levels. In contrast, transfection with the codon-altered K8.1 carrying plasmid ps5/K8.1co
restored VEGF levels to those produced in control samples
derived from either TPA-induced cells or cells transfected with
a plasmid encoding a nonspecific siRNA control (Fig. 3A).
gB is known to bind to ␣V␤3 integrin and induce integrindependent autocrine and paracrine signaling that regulates
VEGF and vIL-6 production (55). To assess whether the gB
RGD amino acid motif was involved in the observed regulation
of VEGF mRNA levels, BCBL-1 cells were transfected with a
plasmid expressing the anti-gB siRNA (ps18) as well as either
the codon-optimized gB (ps18/gBco) or codon-optimized gB
carrying the RGD-to-RAA mutations (ps18/gBR). The anti-gB
siRNA si18 decreased the amount of VEGF transcripts by
approximately 30% compared to that of cells transfected with
a nonspecific siRNA (control). The combined use of both
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FIG. 4. Effect of K8.1 and gB inhibition on vIL-6 production.
BCBL-1 cells were transfected with plasmid vectors expressing nonspecific siRNA, ps5, ps5/K8.1co, ps18, ps18/gBco, and ps5/s10 ⫹
ps18⫹ps22. Cells were induced with TPA 24 h posttransfection, and
cell pellets were collected 16 h postinduction to extract total RNA and
make first-strand cDNA. cDNA from TPA-induced (⫹) or uninduced
(⫺) BCBL-1 cells and without any plasmids were used as controls.
Primers described in Table 1 for vIL-6 amplified a 460-bp DNA fragment, which was visualized by ethidium bromide staining after gel
electrophoresis. Bar graphs represent the densitometric analysis of the
PCR fragment images using Image J software after normalization to
respective GAPDH levels. Experiments were conducted in triplicate,
and error bars represent SEM.

anti-gB and anti-K8.1 siRNAs failed to augment VEGF transcriptional inhibition beyond the level of inhibition produced
by ps5 alone (not shown). The gBco and gBR plasmids rescued
VEGF mRNA to levels similar to those detected in control
BCBL-1 cellular extracts (Fig. 3B). Western immunoblot analysis of BCBL-1 supernatants using anti-VEGF antibody revealed a significant reduction in VEGF secretion when either
gB or K8.1 synthesis was inhibited by siRNAs, in agreement
with the RT-PCR results described above (Fig. 3C).
Inhibition of gB and K8.1 synthesis causes inhibition of
vIL-6 mRNA levels. Previous studies have shown that vIL-6
regulated VEGF levels (5, 6). Therefore, similar experiments
were performed to determine the role of gB and K8.1 inhibition in vIL-6 mRNA levels. These experiments revealed that
the inhibition of either gB or K8.1 synthesis caused a decrease
of vIL-6 mRNA levels by 30 to 40%. The combined use of both
anti-gB and anti-K8.1 siRNAs did not increase the overall
amount of vIL-6 production above that of either the anti-gB or
anti-K8.1 siRNAs used alone (Fig. 4). Transfection with plasmid psK5/K8.1co or ps18/gBco restored vIL-6 levels to those
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detected in mock or nonspecific siRNA control samples (Fig.
4A). To assess whether viral glycoproteins gB and K8.1 in
BCBL-1 cell supernatants were involved in the observed transcriptional regulation of VEGF and vIL-6 genes and angiogenesis, BCBL-1 cells were incubated in the presence of anti-gB or
anti-K8.1 antibodies during the 24-h TPA induction period.
Both anti-gB and K8.1 treatment of BCBL-1 cells caused a
significant decrease in both VEGF and vIL-6 transcription and
VEGF protein synthesis (Fig. 5).
Inhibition of gB and K8.1 synthesis causes substantial reduction in endothelial cell microcapillary formation and migration. VEGF and vIL-6 are potent promoters of angiogenesis in BCBL-1 tumors in mouse animal models (5, 6). To
assess whether the observed reduction of VEGF and vIL-6
mRNA levels affected the behavior of endothelial cells in cell
culture, conditioned medium obtained from BCBL-1 cells
transfected with anti-gB, anti-K8.1, or a combination of both
anti-gB and anti-K8.1 siRNAs was utilized in an in vitro microcapillary formation assay (described in Materials and Methods). These experiments revealed that transfection with
siRNAs inhibited the formation of endothelial cell-derived
capillary-like tubes in cell culture. Importantly, conditioned
medium from BCBL-1 cell cultures treated with the antibodies
exhibited a significantly reduced ability to promote angiogenesis, as evidenced by the reduction in the formation of endothelial cell-derived capillary-like tubes (Fig. 6).
Additional experiments were performed to assess the ability of
conditioned medium obtained from BCBL-1 cells subjected to
anti-gB or anti-K8.1 siRNA inhibition to induce the migration of
HUVEC cells in a Boyden-Chamber migration assay (see Mate-

rials and Methods). Conditioned medium obtained from BCBL-1
cells transfected with either anti-gB or anti-K8.1 siRNAs produced significantly reduced cell migration (an approximately
4-fold decrease) compared to that of medium obtained from
either TPA-induced, nonspecific siRNA-transfected BCBL-1
cells or a VEGF-positive control sample (Fig. 7).
DISCUSSION
KSHV-encoded glycoproteins gB and K8.1 play significant
roles in the life cycle of the virus, primarily because they mediate virus attachment to integrin receptors (gB via its RGD
motif) and heparan sulfate moieties (gB and K8.1) expressed
on cell surfaces. In addition, gB synthesis has been shown to be
important for virion egress, implying a specific role of gB in
intracellular virion trafficking and egress during the lytic cycle
of the virus. Importantly, both gB and gK8.1 have been implicated in signal transduction processes mediated via their binding to integrin and heparan sulfate receptors that most likely
contribute to virus-associated pathogenicity. Of particular interest to the present study is the observation that soluble gB
and, to a greater extent, K8.1 were shown to induce VEGF
synthesis and secretion, suggesting a role of these two viral
glycoproteins in angiogenesis and tumorigenesis (55).
The salient features of the results presented in this study are
(i) the K8.1 glycoprotein is as important as gB in virion egress;
(ii) the gB RGD amino acid motif is not required for virion
egress from BCBL-1 cells; and (iii) the inhibition of either gB
or K8.1 by siRNAs or via the addition of antibodies to gB or
K8.1 into BCBL-1 cultures resulted in a significant reduction in
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FIG. 5. Effect of anti-K8.1 and anti-gB antibody treatment on VEGF and vIL-6 production. BCBL-1 cells were induced (⫹) with TPA for 24 h
or not induced (⫺) in the presence of either anti-gB or anti-K8.1 antibody or in the presence of nonspecific rabbit IgG. After 24 h, medium was
replaced with serum-free medium and collected after incubation for an additional 16 h. (A) Total RNA was extracted from cell pellets, and the
levels of vIL-6 mRNAs were assessed as described in the legend to Fig. 4. (B) The relative levels of VEGF mRNAs also were assessed as described
in the legend to Fig. 3. (C) The relative amounts of VEGF protein expressed in supernatants of BCBL-1 cells treated with the various antibodies
was assessed by the densitometric analysis of Western immunoblots.
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FIG. 6. Effect of K8.1 and gB inhibition on HUVEC microtubule formation. (A) Photomicrographs of HUVEC monolayers treated with
conditioned medium obtained from BCBL-1 cells. BCBL-1 cell supernatants were collected as described in Materials and Methods. HUVECs
seeded in eight-well chamber slides were treated with equal amounts of total protein from BCBL-1 supernatants for 48 h to allow for microtubule
formation. The panel labeled “Microtubule formation” is included to demonstrate the formation of branch points that were counted to obtain the
degree of angiogenesis. (B) The degree of angiogenesis was calculated as a product of the total number of branch points and the number branches
per point. The branch points were counted under 2⫻ magnification. Magnified portions of the cell cultures are shown as insets. Readings from
three random viewing fields were used to generate the bar graphs. Error bars represent SEM.

both VEGF and vIL-6 synthesis and the secretion and substantial reduction in the potential of BCBL-1 cells to induce angiogenesis in vitro. These results support the hypothesis that
the production of viral particles during lytic reactivation
plays an important role in the regulation of VEGF and vIL-6
synthesis via autocrine and/or paracrine signal transduction
pathways.
Role of K8.1 and gB in virion egress and infectivity. We have
reported previously that a KSHV recombinant virus carrying a
deletion of the K8.1 gene produced infectious virion particles
in the supernatants of 293 cells, as evidenced by their ability to
enter into 293 cells (30). However, it was noted that the overall
amount of infectious virions produced in supernatants of 293
cells was fairly small, which is in part attributed to the fact that
these recombinant virions were produced after the transfection
of the K8.1 gene-deleted KSHV genome cloned into a bacterial artificial chromosome (66). In the present study, siRNAs
against K8.1 were utilized to inhibit K8.1A synthesis in
BCBL-1 cells in a manner similar to that of our previous
studies examining the role of gB in virion egress (57). The
results presented in this work strongly suggest that K8.1 plays a
significant role in virion egress that is comparable to that of gB.
The gB RGD motif is known to bind to integrin receptors on

cell surfaces mediating virus attachment and virion entry into
susceptible cells. We considered that gB synthesized in
BCBL-1 cells associates with integrin molecules intracellularly,
prior to gB and integrin complex expression on cell surfaces,
either in the rough endoplasmic reticulum or within Golgi and
trans-Golgi organelles responsible for trafficking both gB and
integrin complex protein components on cell surfaces. However, the mutagenesis of the RGD motif showed that there was
no effect in virion egress from infected cells, suggesting that the
gB RGD motif functions exclusively during virus entry into
cells.
Role of gB and K8.1 in angiogenesis. Generally, the formation of new blood vessels from existing ones is a prerequisite
for the growth and metastatic potential of many tumors (15, 16,
20). Tumor and stromal cells are known to secrete two potent
angiogenic factors, VEGF and basic fibroblast growth factor
(b-FGF) (17, 37). In addition, the physiopathology of hematological malignancies can be affected by these two angiogenic
factors. Specifically, a functional linkage between angiogenesis
and disease progression has been documented for multiple
myelomas (58, 59), non-Hodgkin’s lymphoma (49, 52, 53), and
leukemia (1, 13, 22, 24, 35, 39, 42).
A number of viral cytokines and chemokines are known to
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FIG. 7. Effect of K8.1 and gB inhibition on HUVEC migration. (A) Photomicrographs of endothelial cell migration toward conditioned
medium obtained from BCBL-1 cells. Conditioned medium was collected from BCBL-1 cells treated with either siRNAs or anti-gB and anti-K8.1
antibodies as described in Materials and Methods. Endothelial cells were seeded in the upper chamber of transwell inserts and treated with
conditioned medium for 6 h before taking readings. Cells that migrated to the insert’s bottom surface were stained with hematoxylin and eosin and
counted. (B) Quantification of HUVEC migration. The bar graphs represent the number of cells migrating from the upper chamber to the lower
surface of the transwell insert in each treatment. Results are expressed as cells per 40⫻ objective field. Five regions from each of three inserts per
condition were averaged. Error bars reflect SEM.

be produced by different primary effusion lymphoma (PEL)
cell cultures, including vIL-6 and virally encoded chemokines
(vCCLs). The production and secretion of these factors are
greatly increased upon the TPA-induced reactivation of the
lytic cycle of the virus (29). Similarly, the production and secretion of VEGF and b-FGF are greatly increased upon the
lytic reactivation of the virus. Furthermore, the implantation of
BCBL-1 and PEL cells in mice resulted in a drastic increase of
VEGF and FGF production concomitantly with the detection
of reactivated virus (21). Recently, it was shown that the treatment of endothelial cells in cell culture with VEGF increased
virus entry into cells, suggesting that the presence of VEGF is
a significant factor in virus transmission to proximal and distal
sites following primary infection. Similarly, vIL-6 is a key angiogenic and tumorigenic determinant of PEL-like disease in
murine models and is known to induce VEGF synthesis in vivo
and in vitro (5, 6). Taken together, these results indicate that
the spontaneous reactivation of KSHV lytic replication within
PEL cells in vivo leads to the production of VEGF and vIL-6
that significantly affects virus-associated pathogenicity by in-

creasing the infectivity of excreted virions and the overall angiogenic and tumorigenic potential of PEL tumors.
It has been shown previously that soluble versions of either
gB or K8.1 appear to regulate VEGF-A synthesis (55). However, the fact that gB having its RGD motif changed to RAA
rescued virion egress and both VEGF and vIL-6 production
argues against the involvement of a gB-mediated, integrindependent signal transduction pathway in VEGF/vIL-6 regulation. The fact that the simultaneous use of anti-gB and antiK8.1 siRNAs did not reduce VEGF/vIL-6 production by levels
greater than those observed when either gB or K8.1 was targeted alone suggests that gB and K8.1 act via the same mechanistic pathway. In this regard, it is possible that gB directly or
indirectly interacts and signals as a protein complex with K8.1,
explaining the ability of the RGD-modified gB to rescue
VEGF and vIL-6 synthesis. The anti-gB and anti-K8.1 antibody treatment experiments clearly show that gB and K8.1
found in supernatants and/or infected cell surfaces are responsible for the VEGF and vIL-6 regulation.
Our mechanistic model for explaining the observed phenom-

Downloaded from https://journals.asm.org/journal/jvi on 14 January 2022 by 2620:105:b001:1060:86f:667c:32f5:4ae9.

1712

gB AND K8.1 REGULATE VIRION EGRESS AND ANGIOGENESIS

ena suggests a direct interaction between gB and K8.1 in virion
particles and cell surfaces and their interaction with one or
more plasma membrane receptors that mediate VEGF and
vIL-6 transcriptional regulation. These transduction receptors
may include the known ␣V␤3 and xCT KSHV receptors as well
as the vIL-6 receptor. Finally, gB and K8.1 are not efficiently
secreted in supernatants of BCBL-1 cells as free proteins,
suggesting that most gB and K8.1 is found either in virion
particles or stably immobilized on BCBL-1 cell surfaces. Based
on the observations that BCBL-1 cells do not efficiently aggregate, it can be concluded that virion particles are primarily
responsible for the observed regulation of VEGF and vIL-6
synthesis. Therefore, secreted virion particles play direct and
important roles in angiogenesis. It has been noted that the
KSHV infection of endothelial cells induces a number of other
angiogenic and inflammatory cytokines, such as Ang-2, MMP1,
MMP9, and IL-6 (47, 48, 64, 65). Most likely, these proteins
are upregulated via intracellular pathways that are altered as a
result of KSHV infection. The results presented herein suggest
that the targeted inhibition of gB and/or K8.1 synthesis reduces
the pathogenicity, angiogenicity, and tumorigenicity of the virus in vivo.
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